Table 1 (abstract P16). See text for description
Patient | Age | Pharmacological therapy | Initial assessment | Final evaluation | |||||
|---|---|---|---|---|---|---|---|---|---|
UPDRS (III) score | H&Y | Mini-BEST test | PDQ-39 | UPDRS (III) score | H&Y | Mini-BEST test | |||
A | 71 | Stalevo, Sirio, Sinem et | Limbs’s rigidity (2) sn>dx; remarkable postural instability (3) | 3 | 13/28 | 21% | Limbs’s rigidity (1) sn>dx; remarkable postural instability (1) | 3 | 20/28 |
B | 80 | Azilect, Sinem et | Very important rigidity & tremor to the right (3) postural instability (2) | 3 | 18/28 | 18% | Rigidity dx (2) postural instability (1) | 3 | 21/28 |
C | 63 | Azilect, Sinem et | Limbs’s rigidity (1) hand gesture deficit (2) | 1.5 | 27/28 | 5% | Limbs’s rigidity (1) hand gesture deficit (1) | 1.5 | 28/28 |
D | 67 | Madopal, Azilet, Mirapexil | Deambulation (1) Evident postural instability (3) | 2.5 | 22/28 | 10% | Deambulation (1) Evident postural instability (1) | 2.5 | 25/28 |